A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881

Exclusion Criteria

• •1. Participant is mentally or legally incapacitated or has significant emotional problems at the time of the Screening visit or expected during the conduct of the study.
• •2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the Investigator or designee.
• •3. History of any illness that, in the opinion of the Investigator or designee, might confound the results of the study or pose an additional risk to the participant (e.g., history or presence of rashes) by their participation in the study.
• •4. History of stomach or intestinal surgery that would potentially alter absorption/secretion; or any major surgical procedure within the previous 3 months prior to Screening.
• •5. History of severe and/or uncontrolled ventricular arrhythmias, or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome).
• •6. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.
• •7. History or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds.
• •8. Any positive responses on the C-SSRS.
• •9. Female participants of childbearing potential.
• •10. Female participants with a positive pregnancy test or who are lactating.
• •11. Positive urine drug or alcohol results at Screening or first check-in.
• •12. Positive results at Screening for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies.
• •13. QT interval Fridericia's formula (QTcF) interval is \>450 msec, or QRS interval \>110 msec, or PR interval \>220 msec, or participants who have ECG findings deemed abnormal with clinical significance by the Investigator or designee at Screening.
• •14. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at Screening.
• •15. Seated heart rate is lower than 40 beats per minute (bpm) or higher than 99 bpm at Screening.
• •16. Estimated creatinine clearance \<90 mL/min at Screening.
• •17. Unable to refrain from or anticipates the use of: Any drug, including prescription and non-prescription medications, herbal remedies, and vitamin supplements, beginning 14 days prior to the first dosing and throughout the study. After first dosing, ibuprofen (1.2 g per 24 hour) may be administered at the discretion of Investigator or designee. Hormone replacement therapy will not be allowed; any drugs known to be strong inducers of CYP3A, CYP2C9, or CYP2C19 enzymes including St. John's Wort and/or, gastric acid reducing agents (e.g., proton-pump inhibitors \[with the exception of omeprazole administered as part of the study schedule\], H2-receptor antagonists, antacids) for 28 days, or drugs that can prolong the QT interval for 21 days, prior to the first dosing and throughout the study. Appropriate sources (e.g., Flockhart TableTM) will be consulted to confirm lack of PK/Pharmacodynamic (PD) interaction with study drug.
• •18. Refuses to abstain from alcohol from 48 hours prior to the first dosing and throughout the study.
• •19. Refuses to abstain from grapefruit-containing foods or beverages or Seville orange containing foods or beverages from 14 days prior to the first dosing and throughout the study.
• •20. Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing and throughout the study.
• •21. Any allergy or intolerance to food substances which will be provided on the study.
• •22. Is lactose intolerant.
• •23. Donation of blood or significant blood loss within 56 days prior to the first dose.
• •24. Plasma donation within 7 days prior to the first dose.
• •25. Receipt of blood or blood products within 2 months prior to the first dose.
• •26. Participation in another clinical study within 30 days prior to the first dose. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.